During the first quarter of the 2024 earnings season, large drugmakers Bayer and Bristol Myers Squibb announced thousands of layoffs in two of the largest workforce reductions so far this year. Coming off years of upheaval in the biotech and pharma sectors, will this be a temporary bump in the road or the beginning of a significant wave of Big Pharma layoffs?
The U.S. Food and Drug Administration’s (FDA) staff on Wednesday pointed to “notable imbalance” in incidence of low blood sugar in patients with type 1 diabetes treated with Danish drugmaker Novo Nordisk’s (NOVOb.CO) long-acting weekly insulin.
Despite weathering a difficult year, biopharma continues to see massive pay gaps between CEOs and their median employees, with top executives often earning hundreds of times more.
The company announced today that it had agreed to buy privately held Human Immunology Biosciences for up to $1.8 billion, bulking up on rare disease medicines as its older multiple sclerosis drugs face tepid demand due to rising competition.
The experimental drug was in development to treat agitation and restlessness caused by symptoms of Alzheimer’s disease.
In her new role, Hutnik will lead Spectrum’s global platform of integrated services including enterprise- wide operations and growth planning across the company’s four strategic pillars: Scientific Communications, Advertising & Consulting, Clinical Trial Experience and Spectrum Science Europe.